MATA NATHAN L. 4

What Happened
Nathan L. Mata, Chief Scientific Officer of Belite Bio (BLTE), sold a total of 1,000 American Depositary Shares (ADS) in multiple open-market disposals on May 6, 2026, for aggregate proceeds of approximately $153,840. The sales were executed in six tranches: 8 ADS @ $151.57 ($1,213); 424 ADS @ $152.67 ($64,733); 128 ADS @ $153.42 ($19,638); 240 ADS @ $154.41 ($37,059); 100 ADS @ $155.97 ($15,597); and 100 ADS @ $156.00 ($15,600). Each ADS represents one ordinary share of the issuer.

Key Details

• Transaction date: May 6, 2026; Form 4 filed May 7, 2026 (timely).
• Total shares sold: 1,000 ADS; total proceeds ≈ $153,840.
• Price range across sales: approximately $151.17 to $156.00 (weighted averages reported for groups).
• Reported under sales code S (sale/disposition).
• Footnotes: trades were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025; filer offers to provide per-price breakdowns on request (per footnotes F3–F6).
• Shares owned after the transactions: not disclosed in the provided filing.

Context

• These were scheduled sales under a 10b5-1 plan, which means the trades were prearranged and executed according to that plan rather than ad hoc decisions tied to public announcements.
• Sales are generally treated as routine insider disposals; purchases tend to be more indicative of a direct bullish signal.
• No options exercise, gift, or tax-withholding event is reported in this filing.